Brugada Syndrome Market Highlights

Factors such as the increasing prevalence of heart diseases and rising therapeutics demand are estimated to drive the market growth during the forecast period. Additionally, advancements in diagnostic technologies boost the market. However, low awareness and lack of healthcare services in the middle and low-income countries are estimated to restrain the market growth during the projected period.

The global Brugada syndrome market is expected to grow at a CAGR of 6.4% during the forecast period.

Brugada syndrome is a genetic condition resulting in an abnormal electrical activity within the heart, which in turn increases the risk of sudden cardiac death. In some cases, the abnormal heart rhythm often occurs when a patient is at rest and may be triggered by a fever. However, signs and symptoms of Brugada syndrome include fainting, irregular heartbeats or palpitations, and extremely fast and chaotic heartbeat. The signs and symptoms of Brugada syndrome are similar to some other heart rhythm related problems.

Inquire for Sample Research Report https://www.marketresearchfuture.com/sample_request/5849  

Industry Segmentation

The global Brugada syndrome market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of diagnosis, the market is segmented into

• electrocardiogram,
• Electrophysiology (EP) test,
• genetic testing,
• and others.

On the basis of treatment, the market is segmented into

• implantable cardioverter-defibrillator
• and drug therapy.

Drug therapy is further segmented into Antiarrhythmic Drugs-

• ajmaline,
• allapinin,
• ethacizin,
• flecainide,
• pilsicainide,
• procainamide,
• propafenone,
• and others.

Psychotropic Drugs-

• amitriptyline,
• clomipramine,
• desipramine,
• lithium,
• loxapine,
• nortriptyline,
• trifluoperazine,
• and others.

Anesthetics/Analgesics-

• bupivacaine,
• procaine,
• propofol,
• and others.

On the basis of end-user, the market is segmented into hospitals and clinics, surgical centers, diagnostic centers, and others.

Competitive Analysis by Major Key Players

Some of the key players in this market are GeneDx (U.S), PGxHealth LLC (U.S), Abbott (U.S), GE Healthcare (U.K), Medtronic (U.S.), Pfizer, Inc (U.S), Boston Scientific Corporation (U.S.), GlaxoSmithKline (U.K), Eli Lilly Company (U.S), Taj Pharmaceuticals Ltd (India), and others.

Browse Complete Premium Research Report https://www.marketresearchfuture.com/reports/brugada-syndrome-market-5849  

About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar, Pune

+1 646 845 9312

Email: sales@marketresearchfuture.com